CN111166932B - 一种液体伤口喷剂敷料及其制备方法 - Google Patents
一种液体伤口喷剂敷料及其制备方法 Download PDFInfo
- Publication number
- CN111166932B CN111166932B CN202010131446.3A CN202010131446A CN111166932B CN 111166932 B CN111166932 B CN 111166932B CN 202010131446 A CN202010131446 A CN 202010131446A CN 111166932 B CN111166932 B CN 111166932B
- Authority
- CN
- China
- Prior art keywords
- wound
- dressing
- liquid wound
- liquid
- spray dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 49
- 239000007921 spray Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 206010052428 Wound Diseases 0.000 claims abstract description 96
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 95
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 21
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 21
- 229920001661 Chitosan Polymers 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000008213 purified water Substances 0.000 claims abstract description 18
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000003755 preservative agent Substances 0.000 claims abstract description 10
- 230000002335 preservative effect Effects 0.000 claims abstract description 10
- 229960003600 silver sulfadiazine Drugs 0.000 claims abstract description 8
- 229960004393 lidocaine hydrochloride Drugs 0.000 claims description 8
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 claims description 8
- 238000002791 soaking Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 4
- 235000010234 sodium benzoate Nutrition 0.000 claims description 4
- 239000004299 sodium benzoate Substances 0.000 claims description 4
- 208000002847 Surgical Wound Diseases 0.000 claims description 3
- 238000006136 alcoholysis reaction Methods 0.000 claims description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- 230000006196 deacetylation Effects 0.000 claims description 2
- 238000003381 deacetylation reaction Methods 0.000 claims description 2
- 239000011858 nanopowder Substances 0.000 claims description 2
- 230000001502 supplementing effect Effects 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960002216 methylparaben Drugs 0.000 claims 1
- 229960003885 sodium benzoate Drugs 0.000 claims 1
- 230000029663 wound healing Effects 0.000 abstract description 16
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 13
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 abstract description 12
- 229960004194 lidocaine Drugs 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 10
- 230000002439 hemostatic effect Effects 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 7
- 230000012010 growth Effects 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 244000052616 bacterial pathogen Species 0.000 abstract description 3
- 230000009545 invasion Effects 0.000 abstract description 3
- 230000008439 repair process Effects 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 3
- 229940045110 chitosan Drugs 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 abstract 1
- 229940068984 polyvinyl alcohol Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229920002413 Polyhexanide Polymers 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 238000013168 hemostasis test Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- QQGISFDJEJMKIL-JAIQZWGSSA-N (5z)-5-[[3-(hydroxymethyl)thiophen-2-yl]methylidene]-10-methoxy-2,2,4-trimethyl-1h-chromeno[3,4-f]quinolin-9-ol Chemical compound C1=CC=2NC(C)(C)C=C(C)C=2C2=C1C=1C(OC)=C(O)C=CC=1O\C2=C/C=1SC=CC=1CO QQGISFDJEJMKIL-JAIQZWGSSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000006359 acetalization reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000012237 artificial material Substances 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036782 biological activation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- -1 silver ions Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0076—Sprayable compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于医用敷料领域,具体涉及一种液体伤口喷剂敷料及其制备方法。本发明的液体伤口喷剂敷料包括磺胺嘧啶银、利多卡因、壳聚糖、聚乙烯醇、乙醇、防腐剂和纯化水等原料组分。通过对各组分种类、配比和制备方法的优化设计,可以改善液体伤口敷料的长效抑菌性和止血性,持久抵抗病菌的侵袭,同时可以促使伤口组织有序生长和纹理修复,加快伤口愈合过程。本发明的液体伤口敷料疗效确切,使用安全可靠,制备方法快捷简单,不会对皮肤产生任何刺激作用,具有较好的实用价值和推广应用意义。
Description
技术领域
本发明属于医用敷料领域,具体涉及一种液体伤口喷剂敷料及其制备方法。
背景技术
伤口敷料即是用于伤口的覆盖物或称为保护层,在伤口愈合与治疗过程中可以替代受损皮肤得到暂时性的保护作用,避免或控制伤口感染,提供受创表面适合的愈合环境。随着近年来全球人口的高龄化及慢性病逐年增加,带来慢性伤口的发生机率提升。随着科技进步,医学临床上对于伤口的照护方式也趋向需要更有效率的照护方法,过去传统式之绷带、纱布、棉球等一般敷料已不足够应付现代大量且多样化的伤口状况,临床上需要更有效率的伤口复原医材及更符合多样化疾病伤口的敷料照护。
随着科技及知识的进步,各式人工材质陆续被开发出来作为现代敷料的基质以取代传统敷料,高阶敷料因此孕育而产生。医生结合化工材料、机械、纺织的传统产业技术,大大提升了敷料的性能及创造了更多元化的功用,未来高阶敷料的发展趋势,亦是与健康医疗照护息息相关,使得伤口敷料的材质设计不只是舒适的覆盖伤口而已,并朝向了功能性发展,例如:帮助伤口愈合、含药敷料、针对伤口类型之特化敷料等等。但是其唯一目标,就是以缩短伤口愈合进程及减轻伤口疼痛为最终目的。根据Espicom BusinessIntelligence的统计,2007年全球伤口照护市值约100亿美元,其中先进伤口照护约占46亿美元,并以2位数的速率成长。根据Frost&Sullivan的市场调查,2008年西欧国家的先进敷料市场约为15.2亿美元,年均复合增加率约为16.2%;根据BCC Research的调查,2008年美国的先进敷料市场约为35亿美元,年均复合增加率为11.3%。自2011年起,可以观察到全球高阶敷料市场逐步向上攀升,进而维持在稳定成长状态,平均年复合成长率维持在4.6%,高阶敷料的市场需求增加。
目前治疗伤口的敷料产品,主要适用于小创口、擦伤、切割伤等浅表性创面及周围皮肤的护理,而大的开放性伤口护理时往往需要与其他二级敷料一起使用。常见的伤口敷料产品主要是外用药,有膏状、液体状、粉沫状等。应用较多的是液体状敷料,其主要特点是上药、换药无痛苦。现有的液体敷料产品一般主要用于预防感染,很少具有抗菌止血、促进伤口愈合的作用,伤口愈合仍然需要依靠人体的自身修复作用,因此这类敷料产品的应用效果具有很大的改善空间。
发明内容
本发明所要解决的技术问题就是针对现有液体伤口敷料一般仅用于成膜后覆盖保护伤口的不足,提供一种具有抗菌止血、促进伤口愈合功能的液体伤口喷剂敷料及其制备方法。
为解决上述技术问题,本发明采用的技术方案是:
一种液体伤口喷剂敷料,含有如下重量百分数的原料组分:磺胺嘧啶银0.5-2%,利多卡因0.2-1%,壳聚糖0.5-4%,聚乙烯醇2-8%,乙醇6-20%,防腐剂0.2-2%,纯化水余量。
优选地,所述液体伤口喷剂敷料,含有如下重量百分数的原料组分:磺胺嘧啶银0.8-1.2%,利多卡因0.5-0.8%,壳聚糖1-3%,聚乙烯醇3-6%,乙醇8-16%,防腐剂0.5-1%,纯化水余量。
优选地,所述液体伤口喷剂敷料,含有如下重量百分数的原料组分:磺胺嘧啶银1%,利多卡因0.7%,壳聚糖2%,聚乙烯醇5%,乙醇12%,防腐剂0.8%,纯化水余量。
优选地,所述磺胺嘧啶银是经过微粉化处理的纳米粉末,平均粒径为100-200nm。
优选地,所述利多卡因选自盐酸利多卡因、利多卡因游离碱、利多卡因乳酸盐、利多卡因碳酸盐中的至少一种,平均粒径为50-100nm。
优选地,所述壳聚糖的分子量为60-80万,脱乙酰度大于85%。
优选地,所述聚乙烯醇的聚合度为1800-2000,醇解度90%-96%。
优选地,所述防腐剂选自对羟基苯甲酸乙酯、对羟基苯甲酸甲酯、苯甲酸钠中的至少一种。
进一步地,本发明还提供了液体伤口喷剂敷料在制备外科用创面医用材料中的用途。
进一步地,本发明还提供了液体伤口喷剂敷料的制备方法,包括以下步骤:
(1)将聚乙烯醇加适量纯化水浸泡1-2小时,90-95℃恒温加热至溶解,搅拌均匀,得到溶液A;
(2)将壳聚糖加入适量纯化水中,浸泡分散溶解,得到溶液B;
(3)将防腐剂加乙醇进行溶解,得到溶液C;
(4)将溶液B、溶液C依次加入到溶液A中,随后加入磺胺嘧啶银和利多卡因,补至足量的纯化水,搅拌均匀,即可。
磺胺嘧啶银敷料,不仅具有银离子的广谱抗菌作用,又有磺胺嘧啶的抗菌作用,对绿脓杆菌有强大的抑制作用,同时对革兰阳性菌、革兰阴性菌、酵母菌和其他真菌有良好的抗菌作用。此外,磺胺嘧啶银还具有收敛作用,施于患处后可使创面干燥、结痂,因此对控制创面感染有较好的效果。
利多卡因是一种渗透作用快,弥散广的局麻药。包埋利多卡因的敷料具有止血、止痛的功能。由于仅是接触创面的敷料部分溶解释药,因此不会出现局麻药中毒。
壳聚糖是以甲壳质为原料,再经提炼而成,不溶于水,能溶于稀酸,能被人体吸收。壳聚糖是甲壳质的一级衍生物,其化学结构为带阳离子的高分子碱性多糖聚合物,具有独特的理化性能和生物活化功能,具有良好的成膜性、透气性和生物相溶性,一般形成透明的半渗透软膜,同时还具有抗菌、消炎、止血、减少创面渗出和促进创伤组织再生、修复、愈合的作用,易加工成形,适合作为敷料使用。通过组织病理学观察,在壳聚糖敷料覆盖下,细胞刺激皮肤层修复和组织结构重建,诱导创面快速而有序地愈合,生成良好的新皮肤组织。
聚乙烯醇系白色固体,外型分絮状、颗粒状、粉状三种;无毒无味、无污染,可在80-90℃水中溶解。聚乙烯醇的水溶液有很好的粘接性和成膜性;能耐油类、润滑剂和烃类等大多数有机溶剂;具有长链多元醇酯化、醚化、缩醛化等化学性质,易成膜,其膜的机械性能优良,膜的拉伸强度随聚合度、醇解度升高而增强,一般成硬膜。无毒无味,对皮肤无刺激性,不会引起皮肤过敏。常用于制备医用材料、清洁用品。采用聚乙烯醇作为材料主体,可以用于制备外科创伤敷料、负压引流用敷料。
与现有技术相比,本发明的有益效果是:将具有抑菌作用的磺胺嘧啶银、具有止血止痛作用的利多卡因、具有促进伤口组织愈合再生作用的壳聚糖与成膜性能优异的聚乙烯醇配合使用,使得本发明的液体伤口敷料具有显著的抗菌消炎、止血止痛、促进伤口愈合和成膜保护性等性质。通过对各组分配比和制备方法的优化设计,可以改善液体伤口敷料的长效抑菌性和止血性,持久抵抗病菌的侵袭,同时可以促使伤口组织有序生长和纹理修复,加快伤口愈合过程;所形成的保护膜对创面的贴合性和粘附性良好,可以有效减少创面移动时产生的阻力,持久抵御病菌感染。本发明的液体伤口敷料疗效确切,使用安全可靠,制备方法快捷简单,不会对皮肤产生任何刺激作用,具有较好的实用价值和推广应用意义。
具体实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。所使用的材料、试剂等,如无特殊说明,为可从商业途径得到的试剂和材料。
实验原料:磺胺嘧啶银由上海长海医院提供;盐酸利多卡因天津金耀药业有限公司;壳聚糖购自上海阔泉生物科技有限公司;聚乙烯醇购自阿法埃莎化学有限公司。
实施例1
一种液体伤口喷剂敷料,含有如下重量百分数的原料组分:磺胺嘧啶银0.8%,盐酸利多卡因0.5%,壳聚糖3%,聚乙烯醇6%,乙醇10%,苯甲酸钠0.8%,纯化水余量。
所述液体伤口喷剂敷料的制备方法,包括以下步骤:
(1)将聚乙烯醇加适量纯化水浸泡1.5小时,90℃恒温加热至溶解,搅拌均匀,得到溶液A;
(2)将壳聚糖加入适量纯化水中,浸泡分散溶解,得到溶液B;
(3)将苯甲酸钠加乙醇进行溶解,得到溶液C;
(4)将溶液B、溶液C依次加入到溶液A中,随后加入磺胺嘧啶银和盐酸利多卡因,补至足量的纯化水,搅拌均匀,即可。
实施例2
一种液体伤口喷剂敷料,含有如下重量百分数的原料组分:磺胺嘧啶银1.2%,利多卡因游离碱0.8%,壳聚糖1%,聚乙烯醇3%,乙醇8%,对羟基苯甲酸甲酯0.6%,纯化水余量。
所述液体伤口喷剂敷料的制备方法同实施例1。
实施例3
一种液体伤口喷剂敷料,含有如下重量百分数的原料组分:磺胺嘧啶银1%,盐酸利多卡因0.7%,壳聚糖2%,聚乙烯醇5%,乙醇12%,对羟基苯甲酸乙酯0.8%,纯化水余量。
所述液体伤口喷剂敷料的制备方法同实施例1。
抑菌效果实验
参照2012版《消毒技术规范》,对实施例1-3的液体伤口喷剂敷料进行微生物杀灭效果实验,以质量百分浓度为0.02%的聚六亚甲基双胍水溶液、质量百分浓度为0.5%的碘伏消毒液作为对照组,同时设立不使用任何抗菌剂的空白对照组。实验过程如下:以金黄色葡萄球菌、铜绿假单胞菌、化脓性链球菌、白色念珠菌作为试验菌株,制备浓度为105CFU/ml的菌悬液。用灭菌棉签分别蘸取4种菌液,浸泡到实施例1-3的液体伤口喷剂敷料、质量百分浓度为0.05%的苯氧乙醇水溶液以及质量百分浓度为0.02%的聚六亚甲基双胍水溶液中,浸泡时间为30min。随后,取0.5ml上述受试液体涂于含有牛肉膏蛋白胨培养基(金黄色葡萄球菌、铜绿假单胞菌、化脓性链球菌)和马铃薯琼脂培养基(白色念珠菌)的无菌平板中,培养48h、72h,菌落计数,根据空白组的菌落数来计算抑菌率。实验结果如表1所示。
表1.液体伤口喷剂敷料的抑菌效果实验(抑菌率)
由表1的实验结果可知,本发明的液体伤口喷剂敷料具有良好的微生物杀灭效果,对金黄色葡萄球菌、铜绿假单胞菌、化脓性链球菌、白色念珠菌的杀灭率均在98%以上,灭菌效果优于对照组的0.02%的聚六亚甲基双胍水溶液和0.5%的碘伏消毒液。以上结果证明,本发明的液体伤口喷剂敷料具有宽泛的抗菌谱,可以有效抑制微生物的生长,降低伤口感染的发生率,能够较好适用于皮肤黏膜、机械损伤、手术开刀等开放性伤口的长效抑菌保护。
止血实验
选取40只体重5kg的白兔,随机分为4组,每组10只,分别对应于实施例1-3的液体伤口喷剂敷料以及市售的创面抗菌喷剂敷料(创灵牌,主要成分为壳聚糖溶液)。将白兔固定在解剖台上,麻醉后逐层开腹,用无菌纱布吸干腹腔、腹壁上的组织液和血液,暴露肝脏。在肝叶上开具0.8cm×0.8cm×0.5cm的创面,在创面形成过程中渗血先用无菌医用纱布吸收,然后将实施例1-3的液体伤口喷剂敷料和市售的创面抗菌喷剂敷料喷至伤口创面(距离创面约5-8cm),必要时以无菌纱布覆盖,用秒表计时,观察止血效果,待完全止血后,记录止血时间。
表2.止血实验(时间,s)
实施例1 | 实施例2 | 实施例3 | 对照组 | |
止血时间 | 8.6±0.4s | 8.9±0.5s | 8.2±0.4s | 13.1±0.5s |
由表2的实验结果可知,本发明的液体伤口喷剂敷料具有更加优异的止血效果,止血时间明显低于同类的市售产品,可以起到快速止血的作用。
伤口愈合试验
选取40只SD大鼠,随机分为4组,每组10只,分别对应于实施例1-3的液体伤口喷剂敷料以及市售的创面抗菌喷剂敷料(创灵牌,主要成分为壳聚糖溶液)。每只大鼠按1.5ml/kg经腹腔注射10%水合氯醛进行麻醉,除去背毛后,对皮肤进行消毒。在每一只大鼠背后去毛处切出一个面积为1.5cm2大小的完整厚度伤口。然后,将实施例1-3的液体伤口喷剂敷料和市售的创面抗菌喷剂敷料喷至伤口创面(距离创面约5-8cm),每天早晚在伤口处局部喷药各一次,分别于喷药后的第3、6、9、12天观察大鼠伤口愈合情况。测量伤口长度和宽度,计算伤口面积和伤口愈合率,伤口愈合率=(初始伤口面积-第n天测量伤口面积)/初始伤口面积×100%,实验结果如表3所示。
表3.液体伤口喷剂敷料对大鼠伤口的促愈合试验
由表3的试验结果可知,本发明的液体伤口喷剂敷料对大鼠伤口具有明显的促愈合作用。与市售的创面抗菌喷剂敷料相比,本发明的液体伤口喷剂敷料能够明显缩短伤口愈合时间,在12d时间内伤口愈合率可达到93%以上,明显优于对照组,进而实现伤口快速愈合,同时能促使伤口新生组织快速、有序生长。本发明的液体伤口喷剂敷料疗效确切,使用安全可靠,不会对皮肤产生任何刺激作用,拥有很好的成膜性能,在保护伤口的同时能够促进伤口愈合,持久抵抗病菌的侵袭,具有较好的实用价值和推广应用意义。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (8)
1.一种液体伤口喷剂敷料,其特征在于,含有如下重量百分数的原料组分:磺胺嘧啶银0.8-1.2%,盐酸利多卡因0.5-0.8%,壳聚糖1-3%,聚乙烯醇3-6%,乙醇8-16%,防腐剂0.5-1%,纯化水余量。
2.根据权利要求1所述的液体伤口喷剂敷料,其特征在于,含有如下重量百分数的原料组分:磺胺嘧啶银1%,盐酸利多卡因0.7%,壳聚糖2%,聚乙烯醇5%,乙醇12%,防腐剂0.8%,纯化水余量。
3.根据权利要求1或2所述的液体伤口喷剂敷料,其特征在于,所述磺胺嘧啶银是经过微粉化处理的纳米粉末,平均粒径为100-200nm。
4.根据权利要求1或2所述的液体伤口喷剂敷料,其特征在于,所述壳聚糖的分子量为60-80万,脱乙酰度大于85%。
5.根据权利要求1或2所述的液体伤口喷剂敷料,其特征在于,所述聚乙烯醇的聚合度为1800-2000,醇解度90%-96%。
6.根据权利要求1或2所述的液体伤口喷剂敷料,其特征在于,所述防腐剂选自对羟基苯甲酸乙酯、对羟基苯甲酸甲酯、苯甲酸钠中的至少一种。
7.根据权利要求1-6任一项所述的液体伤口喷剂敷料在制备外科用创面医用材料中的用途。
8.根据权利要求1-6任一项所述的液体伤口喷剂敷料的制备方法,其特征在于,包括以下步骤:
(1)将聚乙烯醇加适量纯化水浸泡1-2小时,90-95℃恒温加热至溶解,搅拌均匀,得到溶液A;
(2)将壳聚糖加入适量纯化水中,浸泡分散溶解,得到溶液B;
(3)将防腐剂加乙醇进行溶解,得到溶液C;
(4)将溶液B、溶液C依次加入到溶液A中,随后加入磺胺嘧啶银和盐酸利多卡因,补至足量的纯化水,搅拌均匀,即可。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010131446.3A CN111166932B (zh) | 2020-02-29 | 2020-02-29 | 一种液体伤口喷剂敷料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010131446.3A CN111166932B (zh) | 2020-02-29 | 2020-02-29 | 一种液体伤口喷剂敷料及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111166932A CN111166932A (zh) | 2020-05-19 |
CN111166932B true CN111166932B (zh) | 2021-01-26 |
Family
ID=70626106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010131446.3A Active CN111166932B (zh) | 2020-02-29 | 2020-02-29 | 一种液体伤口喷剂敷料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111166932B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113827565A (zh) * | 2020-06-16 | 2021-12-24 | 深圳长久康联生物科技有限公司 | 一种抗感染喷剂敷料及其制备方法、应用 |
CN112057670A (zh) * | 2020-09-30 | 2020-12-11 | 贯皓医疗科技(惠州市)有限公司 | 一种创伤液体敷料 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1410072A (zh) * | 2002-11-15 | 2003-04-16 | 陈延龙 | 磺胺嘧啶银甲壳胺粉剂 |
CN1514706A (zh) * | 2001-01-09 | 2004-07-21 | ��˹���������дĻ� | 治疗性成膜组合物及其治疗系统 |
CN104013574A (zh) * | 2014-05-04 | 2014-09-03 | 莱普德制药有限公司 | 可温变性无痛纳米磺胺嘧啶金属化合物透明质酸的混悬制剂 |
CN104352437A (zh) * | 2014-10-09 | 2015-02-18 | 南京泽恒医药技术开发有限公司 | 一种可用于烧伤、烫伤的喷雾成膜制剂 |
WO2015060786A1 (en) * | 2013-10-21 | 2015-04-30 | Advanced First Aid Research Pte. Ltd. | Spray-on burn dressing |
CN105251011A (zh) * | 2015-11-13 | 2016-01-20 | 谭惠娟 | 一种用于浅度烧伤的喷膜剂及其制备方法 |
CN105903068A (zh) * | 2016-06-02 | 2016-08-31 | 四川奎星医用高分子制品有限责任公司 | 含有镇痛药物的医用复合壳聚糖凝胶 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180236009A1 (en) * | 2017-02-22 | 2018-08-23 | San Melix Laboratories, Inc. | Buckwheat honey and bacitracin wound-healing dressing |
-
2020
- 2020-02-29 CN CN202010131446.3A patent/CN111166932B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1514706A (zh) * | 2001-01-09 | 2004-07-21 | ��˹���������дĻ� | 治疗性成膜组合物及其治疗系统 |
CN1410072A (zh) * | 2002-11-15 | 2003-04-16 | 陈延龙 | 磺胺嘧啶银甲壳胺粉剂 |
WO2015060786A1 (en) * | 2013-10-21 | 2015-04-30 | Advanced First Aid Research Pte. Ltd. | Spray-on burn dressing |
CN104013574A (zh) * | 2014-05-04 | 2014-09-03 | 莱普德制药有限公司 | 可温变性无痛纳米磺胺嘧啶金属化合物透明质酸的混悬制剂 |
CN104352437A (zh) * | 2014-10-09 | 2015-02-18 | 南京泽恒医药技术开发有限公司 | 一种可用于烧伤、烫伤的喷雾成膜制剂 |
CN105251011A (zh) * | 2015-11-13 | 2016-01-20 | 谭惠娟 | 一种用于浅度烧伤的喷膜剂及其制备方法 |
CN105903068A (zh) * | 2016-06-02 | 2016-08-31 | 四川奎星医用高分子制品有限责任公司 | 含有镇痛药物的医用复合壳聚糖凝胶 |
Also Published As
Publication number | Publication date |
---|---|
CN111166932A (zh) | 2020-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schoukens | Bioactive dressings to promote wound healing | |
EP1216065B1 (en) | Silver-containing compositions, devices and methods for making | |
US6605751B1 (en) | Silver-containing compositions, devices and methods for making | |
CN107617121B (zh) | 一种皮肤创面生物诱导活性敷料及其制备方法和应用 | |
CN1850291A (zh) | 具有促进伤口愈合、抗菌功能的液体伤口敷料 | |
CN109432481A (zh) | 一种止血抗菌的聚氨酯敷料及其制备方法 | |
CN111166932B (zh) | 一种液体伤口喷剂敷料及其制备方法 | |
Kaya et al. | Properties of ideal wound dressing | |
CN111068103B (zh) | 一种手术伤口用长效抑菌凝胶敷料及其制备方法 | |
CN110859989B (zh) | 一种液体创可贴及其制备方法 | |
CN113018499A (zh) | 一种杀菌抗病毒吸湿的臭氧油水凝胶复合敷贴的制备方法 | |
CN105169455A (zh) | 一种烧烫伤外用急救医用敷料及其制备方法 | |
CN104740141B (zh) | 一种抗菌喷剂及其制备方法 | |
Fletes-Vargas et al. | Natural hydrogels as wound dressing for skin wound-healing applications | |
CN109432483B (zh) | 一种加速创面愈合的医用敷料及其制备方法和应用 | |
CN112426562A (zh) | 一种促进伤口愈合的纯天然医用敷料 | |
US11058712B2 (en) | Film for topical application in the treatment of skin lesions and method of obtaining and applying same | |
CN113855849A (zh) | 一种敷料组合物及其制备方法和应用 | |
CN109010907B (zh) | 一种功能性护创液体敷料及其制备方法 | |
CN110251716B (zh) | 一种伤口护理用凝胶敷料及其制备方法 | |
KR20190098269A (ko) | 유니티올 및 디메틸설폭사이드를 포함하는 방부제 조성물, 조성물의 용도 및 이를 사용하여 상처를 치료하는 방법 | |
CN112245648B (zh) | 一种消炎抑菌的水胶体油纱及其制备方法 | |
CN108096276A (zh) | 一种清创愈合洗液及其应用 | |
RU2284824C1 (ru) | Клей хирургический антисептический "аргакол" | |
CN102357258A (zh) | 一种结合湿润烧伤膏治疗烧伤的敷料的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Liquid wound spray dressing and its preparation method Effective date of registration: 20221122 Granted publication date: 20210126 Pledgee: Industrial Bank Co.,Ltd. Haikou Branch Pledgor: HAINAN MIAOYINCHUN PHARMACEUTICAL CO.,LTD. Registration number: Y2022980023064 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |